AACHEN, Germany--(BUSINESS WIRE)--PAION AG (FWB:PA8) announced today that the company is now actively seeking a new US-partner for its lead compound Desmoteplase.
While the last Desmoteplase Phase III stroke study initially led to inconclusive results, a re-analysis of the data yielded a sound rationale for the further development of the compound with an adjusted study design, namely by focusing on patients with obstructed major brain arteries. For these patients the data from phase II and phase III Desmoteplase studies suggest a therapeutic benefit although the results fell short of any statistical significance due to the low patient numbers of the subgroups.
